dailyai.report

Rakovina Therapeutics closed its first financing tranche and upsized its private placement to fund its AI-powered oncology platform. The company expanded its strategic investor base to accelerate drug discovery. This capital injection supports the development of targeted cancer therapies. Practitioners should view this as a standard funding milestone for a niche AI-biotech startup.